The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 3, 2006, Pages 377-384

  Jakubowski, Joseph A ^a   Payne, Christopher D ^a   Brandt, John T ^a   Weerakkody, Govinda J ^a   Farid, Nagy A ^a   Small, David S ^a   Naganuma, Hideo ^b   Li, Grace Ying ^a   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

ADP receptors; Antiplatelet agents; CS 747; P2Y12; Prasugrel; Thienopyridine

Indexed keywords

ADENOSINE DIPHOSPHATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; PLACEBO; PRASUGREL; R 106583; R 119251; R 138727; R 95913; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOMA; HUMAN; LIVER FUNCTION TEST; MAINTENANCE DRUG DOSE; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; BLEEDING TIME; DRUG EFFECT; MIDDLE AGED;

ADENOSINE DIPHOSPHATE; ADULT; BLEEDING TIME; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THIOPHENES;

EID: 33745699564     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000210069.47205.c0     Document Type: Article

References (30)

1. Badimon L, Badimon JJ, Fuster V. Pathophysiology of arterial thrombosis. In: Gresele P, Page C, Fuster V, Vermylen J, eds. Platelets in Thrombotic and Non Thrombotic Disorders. 1st ed. New York, NY: Cambridge University Press; 2002:727-737.
2. Goldschmidt PJ, Lopes N, Crawford LE. Atherosclerosis and coronary artery disease. In: Michelson AD, ed. Platelets. 1st ed. San Diego, CA: Elsevier Science USA; 2002:375-398.
3. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects-the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S-264S.
4. Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA. 2004;292:1875-1882.
5. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624-632.
6. Gachet C. Regulation of platelet functions by P2 receptors. Ann Rev Pharmacol Toxicol. 2006;46:277-300.
7. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86:222-232.
8. Solet DJ, Zacharski LR, Plehn JF. The role of adenosine 5′-diphosphate receptor blockade in patients with cardiovascular disease. Am J Med. 2001;111:45-53.
9. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
10. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
11. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood. 2003;101:3908-3914.
12. Thebault J-JR, Kieffer G, Lowe GDO, et al. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost. 1999;25:9-14.
13. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets-results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153-1159.
14. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001;85:92-93.
15. Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005;31:184-194.
16. Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446.
17. Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol. 2001;132:47-54.
18. Payne CD, Brandt JT, Weerakkody G, et al. Superior inhibition of platelet aggregation following a loading dose of CS-747 (Prasugrel, LY640315) versus clopidogrel: correlation with the pharmacokinetics of active metabolite generation. J Thromb Haemost. 2005;3(Suppl 1):P0952.
19. Asai F, Jakubowski J, Naganuma H, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets. 2006. In Press.
20. Asai F, Jakubowski J, Naganuma H, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor: a multible-dose study in healthy humans. Platelets. 2006. In Press.
21. Ivy AC, Nelson D, Bercher G. The standardization of certain factors in the cutaneous venostasis bleeding time technique. J Lab Clin Med. 1941;26:1812-1822.
22. Sheiner LB, Steiner JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol. 2000;40:67-95.
23. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000;20:2316-2321.
24. Moore SA, Steinhubl SR. Clopidogrel and coronary stenting: what is the next question? J Thromb Thrombolysis. 2000;10:121-126.
25. Farid NA, Smith RL, Rash TJ, et al. The disposition of prasugrel (CS-747, LY640315), a novel thienopyridine, in humans. Drug Metab Rev. 2005;37:86.
26. Kazui M, Kurihara A, Hagihara K, et al. Prasugrel (CS-747, LY640315), a novel thienopyridine antiplatelet agent, more efficiently generates active metabolite compared to clopidogrel. Drug Metab Rev. 2005;37:86.
27. Hasegawa M, Sugidachi A, Ogawa T, et al. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005;94:593-598.
28. De Caterina R, Sicari R, Bernini W, et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost. 1991;65:504-510.
29. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38:710-713.
30. Mielke CH Jr, Kaneshiro MM, Maher IA, et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969;34:204-215.